Anavex生命科学 AVXL 深 沪
等待开盘 08-13 09:30:00 美东时间
10.78
-0.570
-5.02%
华盛通- 最 高11.70
- 今 开11.32
- 成交量 163.00万股
- 最 低 10.50
- 昨 收 11.35
- 总市值 9.21亿
- 52周最高 14.4405
- 市盈率 静 --
- 换手率 1.91%
- 52周最低 4.9301
- 委 比 74.46%
- 总股本 8541.67万
- 历史最高 31.50
- 量 比 2.06
- 振 幅 10.57%
- 历史最低 0.60
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anavex Life Sciences Q3 EPS $(0.16) Misses $(0.14) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.89 percent. This is a 14.29 percent decrease over losses of $(0.14) per share
08-12 19:30
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its Q3 2025 financial results, highlighting progress in developing non-invasive treatments for Alzheimer's disease. The company presented positive data on blarcamesine, showing sustained benefits in early-stage Alzheimer's patients. Financially, the company has $101.2 million in cash, with an estimated 3+ years of cash runway. The net loss for the quarter was $13.2 million, or $0.16 per share, compared to $12.2...
08-12 11:30
What to Expect from Anavex Life Sciences's Earnings
Anavex Life Sciences (NASDAQ:AVXL) will release its quarterly earnings report o...
08-11 23:03
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025
<p>Anavex Life Sciences Corp. (Nasdaq: AVXL) will release its third fiscal quarter financial results on August 12, 2025, at 8:30 am ET. A conference call and webcast will discuss the results and growth strategy, followed by a Q&A session. The webcast will be available on www.anavex.com. Participants in the U.S. can join via dial-in: 1 929 205 6099 (Meeting ID: 856 5033 5285, Passcode: 014 352). The replay will be accessible on Anavex’s website fo...
08-05 11:30
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Anavex Life Sciences Corp. announced positive findings for blarcamesine, an oral treatment for early Alzheimer's disease, presented at the 2025 Alzheimer’s Association International Conference (AAIC). Data from the ATTENTION-AD trial showed significant cognitive and functional improvements in early-start patients, with a “time saved” of up to 84.6 weeks. Blarcamesine restored autophagy, targeting SIGMAR1, and demonstrated a favorable safety profi...
07-31 11:30
美股牛股 | 肠炎新药临床试验进展积极，ABVX飙涨超580%！ANEB大涨超80%
肠炎新药临床试验进展积极，ABVX飙涨超580%！公司宣布高溢价私有化计划，ANEB大涨超80%>>
07-24 19:53
Anavex Life Sciences Amends Executive Employment Contracts
An update from Anavex Life Sciences ( ($AVXL) ) is now available. On July 3, 20...
07-04 05:50
